Costs of care for persons with opioid dependence in commercial integrated health systems.

Frances L. Lynch, Dennis McCarty, Jennifer Mertens, Nancy A. Perrin, Carla A. Green, Sujaya Parthasarathy, John F. Dickerson, Bradley M. Anderson, David Pating

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

When used in general medical practices, buprenorphine is an effective treatment for opioid dependence, yet little is known about how use of buprenorphine affects the utilization and cost of health care in commercial health systems. The objective of this retrospective cohort study was to examine how buprenorphine affects patterns of medical care, addiction medicine services, and costs from the health system perspective. Individuals with two or more opioid-dependence diagnoses per year, in two large health systems (System A: n = 1836; System B: n = 4204) over the time span 2007-2008 were included. Propensity scores were used to help adjust for group differences. Patients receiving buprenorphine plus addiction counseling had significantly lower total health care costs than patients with little or no addiction treatment (mean health care costs with buprenorphine treatment = $13,578; vs. mean health care costs with no addiction treatment = $31,055; p <.0001), while those receiving buprenorphine plus addiction counseling and those with addiction counseling only did not differ significantly in total health care costs (mean costs with counseling only: $17,017; p = .5897). In comparison to patients receiving buprenorphine plus counseling, those with little or no addiction treatment had significantly greater use of primary care (p <.001), other medical visits (p = .001), and emergency services (p = .020). Patients with counseling only (compared to patients with buprenorphine plus counseling) used less inpatient detoxification (p <.001), and had significantly more PC visits (p = .001), other medical visits (p = .005), and mental health visits (p = .002). Buprenorphine is a viable alternative to other treatment approaches for opioid dependence in commercial integrated health systems, with total costs of health care similar to abstinence-based counseling. Patients with buprenorphine plus counseling had reduced use of general medical services compared to the alternatives.

Original languageEnglish (US)
Pages (from-to)16
Number of pages1
JournalAddiction science & clinical practice
Volume9
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Buprenorphine
Opioid Analgesics
Counseling
Health Care Costs
Costs and Cost Analysis
Health
Therapeutics
Patient Acceptance of Health Care
Propensity Score
General Practice
Health Services
Inpatients
Primary Health Care
Mental Health
Emergencies
Cohort Studies
Retrospective Studies
Medicine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Costs of care for persons with opioid dependence in commercial integrated health systems. / Lynch, Frances L.; McCarty, Dennis; Mertens, Jennifer; Perrin, Nancy A.; Green, Carla A.; Parthasarathy, Sujaya; Dickerson, John F.; Anderson, Bradley M.; Pating, David.

In: Addiction science & clinical practice, Vol. 9, 2014, p. 16.

Research output: Contribution to journalArticle

Lynch, FL, McCarty, D, Mertens, J, Perrin, NA, Green, CA, Parthasarathy, S, Dickerson, JF, Anderson, BM & Pating, D 2014, 'Costs of care for persons with opioid dependence in commercial integrated health systems.', Addiction science & clinical practice, vol. 9, pp. 16. https://doi.org/10.1186/1940-0640-9-16
Lynch, Frances L. ; McCarty, Dennis ; Mertens, Jennifer ; Perrin, Nancy A. ; Green, Carla A. ; Parthasarathy, Sujaya ; Dickerson, John F. ; Anderson, Bradley M. ; Pating, David. / Costs of care for persons with opioid dependence in commercial integrated health systems. In: Addiction science & clinical practice. 2014 ; Vol. 9. pp. 16.
@article{fbf73a345f034966a2cb3bbdf5ea1b7b,
title = "Costs of care for persons with opioid dependence in commercial integrated health systems.",
abstract = "When used in general medical practices, buprenorphine is an effective treatment for opioid dependence, yet little is known about how use of buprenorphine affects the utilization and cost of health care in commercial health systems. The objective of this retrospective cohort study was to examine how buprenorphine affects patterns of medical care, addiction medicine services, and costs from the health system perspective. Individuals with two or more opioid-dependence diagnoses per year, in two large health systems (System A: n = 1836; System B: n = 4204) over the time span 2007-2008 were included. Propensity scores were used to help adjust for group differences. Patients receiving buprenorphine plus addiction counseling had significantly lower total health care costs than patients with little or no addiction treatment (mean health care costs with buprenorphine treatment = $13,578; vs. mean health care costs with no addiction treatment = $31,055; p <.0001), while those receiving buprenorphine plus addiction counseling and those with addiction counseling only did not differ significantly in total health care costs (mean costs with counseling only: $17,017; p = .5897). In comparison to patients receiving buprenorphine plus counseling, those with little or no addiction treatment had significantly greater use of primary care (p <.001), other medical visits (p = .001), and emergency services (p = .020). Patients with counseling only (compared to patients with buprenorphine plus counseling) used less inpatient detoxification (p <.001), and had significantly more PC visits (p = .001), other medical visits (p = .005), and mental health visits (p = .002). Buprenorphine is a viable alternative to other treatment approaches for opioid dependence in commercial integrated health systems, with total costs of health care similar to abstinence-based counseling. Patients with buprenorphine plus counseling had reduced use of general medical services compared to the alternatives.",
author = "Lynch, {Frances L.} and Dennis McCarty and Jennifer Mertens and Perrin, {Nancy A.} and Green, {Carla A.} and Sujaya Parthasarathy and Dickerson, {John F.} and Anderson, {Bradley M.} and David Pating",
year = "2014",
doi = "10.1186/1940-0640-9-16",
language = "English (US)",
volume = "9",
pages = "16",
journal = "Addiction science & clinical practice",
issn = "1940-0632",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Costs of care for persons with opioid dependence in commercial integrated health systems.

AU - Lynch, Frances L.

AU - McCarty, Dennis

AU - Mertens, Jennifer

AU - Perrin, Nancy A.

AU - Green, Carla A.

AU - Parthasarathy, Sujaya

AU - Dickerson, John F.

AU - Anderson, Bradley M.

AU - Pating, David

PY - 2014

Y1 - 2014

N2 - When used in general medical practices, buprenorphine is an effective treatment for opioid dependence, yet little is known about how use of buprenorphine affects the utilization and cost of health care in commercial health systems. The objective of this retrospective cohort study was to examine how buprenorphine affects patterns of medical care, addiction medicine services, and costs from the health system perspective. Individuals with two or more opioid-dependence diagnoses per year, in two large health systems (System A: n = 1836; System B: n = 4204) over the time span 2007-2008 were included. Propensity scores were used to help adjust for group differences. Patients receiving buprenorphine plus addiction counseling had significantly lower total health care costs than patients with little or no addiction treatment (mean health care costs with buprenorphine treatment = $13,578; vs. mean health care costs with no addiction treatment = $31,055; p <.0001), while those receiving buprenorphine plus addiction counseling and those with addiction counseling only did not differ significantly in total health care costs (mean costs with counseling only: $17,017; p = .5897). In comparison to patients receiving buprenorphine plus counseling, those with little or no addiction treatment had significantly greater use of primary care (p <.001), other medical visits (p = .001), and emergency services (p = .020). Patients with counseling only (compared to patients with buprenorphine plus counseling) used less inpatient detoxification (p <.001), and had significantly more PC visits (p = .001), other medical visits (p = .005), and mental health visits (p = .002). Buprenorphine is a viable alternative to other treatment approaches for opioid dependence in commercial integrated health systems, with total costs of health care similar to abstinence-based counseling. Patients with buprenorphine plus counseling had reduced use of general medical services compared to the alternatives.

AB - When used in general medical practices, buprenorphine is an effective treatment for opioid dependence, yet little is known about how use of buprenorphine affects the utilization and cost of health care in commercial health systems. The objective of this retrospective cohort study was to examine how buprenorphine affects patterns of medical care, addiction medicine services, and costs from the health system perspective. Individuals with two or more opioid-dependence diagnoses per year, in two large health systems (System A: n = 1836; System B: n = 4204) over the time span 2007-2008 were included. Propensity scores were used to help adjust for group differences. Patients receiving buprenorphine plus addiction counseling had significantly lower total health care costs than patients with little or no addiction treatment (mean health care costs with buprenorphine treatment = $13,578; vs. mean health care costs with no addiction treatment = $31,055; p <.0001), while those receiving buprenorphine plus addiction counseling and those with addiction counseling only did not differ significantly in total health care costs (mean costs with counseling only: $17,017; p = .5897). In comparison to patients receiving buprenorphine plus counseling, those with little or no addiction treatment had significantly greater use of primary care (p <.001), other medical visits (p = .001), and emergency services (p = .020). Patients with counseling only (compared to patients with buprenorphine plus counseling) used less inpatient detoxification (p <.001), and had significantly more PC visits (p = .001), other medical visits (p = .005), and mental health visits (p = .002). Buprenorphine is a viable alternative to other treatment approaches for opioid dependence in commercial integrated health systems, with total costs of health care similar to abstinence-based counseling. Patients with buprenorphine plus counseling had reduced use of general medical services compared to the alternatives.

UR - http://www.scopus.com/inward/record.url?scp=84907722062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907722062&partnerID=8YFLogxK

U2 - 10.1186/1940-0640-9-16

DO - 10.1186/1940-0640-9-16

M3 - Article

C2 - 25123823

AN - SCOPUS:84907722062

VL - 9

SP - 16

JO - Addiction science & clinical practice

JF - Addiction science & clinical practice

SN - 1940-0632

ER -